The study was conducted on mice with genes for Alzheimer's disease, which had a reduced number of dendritic spines responsible for memory formation. The introduction of EDR and KED peptides helped to significantly increase their number. This means that in mice with genes for Alzheimer's disease, there a complete restoration of brain functions was observed. It is noteworthy that those peptide drugs are safe and have no side effects.
Currently, the development of this unique Russian peptide drug for the treatment of Alzheimer's disease is at the final stage of preclinical studies. The next stage will be the submission of documents to the Ministry of Health of the Russian Federation for permission to conduct clinical trials already in humans. This is planned to be done after 2022.
Read the full text of the article “Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer’s Disease”.
https://www.mdpi.com/1424-8247/14/6/515/html